The effect of pregabalin for pain after third molar surgery: a systematic review and meta-analysis Authors: Jie Li, Anli Wang Published: 2026 ABSTRACT AbstractBackgroundPregabalin has been proposed as an adjunct for postoperative pain management following third molar surgery, but its analgesic efficacy, safety, and clinical applicability remain uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) ascertaining pregabalin for pain after third molar extraction.MethodsA systematic search was conducted across PubMed, Scopus, Web of Science, and Google Scholar up to January 2025. RCTs appraising pregabalin for postoperative pain following third molar surgery were included. The primary outcome was pain intensity (VAS) and the secondary outcome was adverse events (AEs). Data were pooled using a random-effects meta-analysis, with mean difference (MD) for pain scores and odds ratio (OR) for AEs, each with 95% confidence intervals (CIs). Risk of bias was assessed using the Cochrane RoB 2 tool.ResultsSix RCTs involving 545 patients undergoing third molar surgery were included. Of these, 170 patients (4 RCTs) contributed data to the quantitative synthesis. Pregabalin significantly mitigated postoperative pain compared with control (MD − 0.99, 95% CI − 1.46 to − 0.52, p < 0.00001), though substantial heterogeneity was observed (I²=91%). Subgroup analysis by timepoint revealed consistent but individually nonsignificant reductions in pain at 2–24 h postoperatively. Pregabalin use was linked to a higher risk of adverse events (OR 4.36, 95% CI 2.52–7.55, p < 0.00001, I²=77%), with a dose–response effect observed (ORs: 1.18 for 50 mg, 5.19 for 75 mg, 11.16 for 300 mg). Risk of bias was high or raised some concerns in three of the six included trials, with the certainty of evidence being limited by the substantial heterogeneity.ConclusionsPregabalin may provide a modest reduction in postoperative pain following third molar surgery; however, the clinical relevance and robustness of this benefit remain uncertain due to substantial heterogeneity and sensitivity to a single study. In contrast, pregabalin was consistently associated with an increased risk of adverse events. Therefore, the benefit–harm balance does not clearly support routine use of pregabalin as a first-line analgesic in this setting. Further high-quality, placebo-controlled RCTs with standardized dosing, comparator groups, and postoperative assessment timepoints are needed.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-04000-w.Keywords: Pregabalin, Third molar surgery, Wisdom tooth extraction, Postoperative pain, Adverse events, Meta-analysis Background Third molar surgery is among the most common outpatient interventions in oral and maxillofacial surgery. In the context of third molar surgery, postoperative pain represents one of the most common and distressing complications, often impairing daily activities and overall comfort [1]. The pain is generally of short to moderate duration, with its peak intensity typically occurring within the first 12 h post-surgery, before gradually subsiding [2]. Accordingly, effective pain control is a critical component of perioperative management in oral and maxillofacial surgery. Indeed, an ideal analgesic for postoperative management of third molar surgery would effectively control pain, lower swelling and trismus, while also carrying minimal risk of adverse effects. Whereas no single agent fulfills all of these criteria, currently available medications can provide sufficient relief to support an uncomplicated recovery [3]. Pregabalin, a structural analogue of gamma-aminobutyric acid (GABA), acts by binding to the α2δ subunit of voltage-gated calcium channels in the central nervous system, thereby curtailing excitatory neurotransmitter release [4, 5]. Originally developed as an antiepileptic, pregabalin has demonstrated efficacy in neuropathic pain and as part of multimodal analgesia for various surgical procedures [6, 7]. Its potential benefits in mitigating both acute nociceptive and neuropathic pain mechanisms make it an attractive candidate for postoperative pain management following third molar surgery [8–11]. Over the past decade, some randomized controlled trials (RCTs) have explored the effect of pregabalin in this setting. Nevertheless, no comprehensive consensus has been established regarding the efficacy of pregabalin for pain control after third molar surgery. With a definitive consensus lacking, it is necessary to synthesize the available evidence through a systematic review and meta-analysis. By synthesizing data from published RCTs, this study aims to appraise the effectiveness of pregabalin in alleviating postoperative pain following third molar surgery, as well as to assess its associated adverse effects as the secondary outcome to provide insight into its short-term postoperative tolerability. Through consolidating current findings, this review seeks to provide clearer, evidence-based guidance for clinical decision-making. Methods Eligibility criteria We included RCTs that assessed the impact of pregabalin on postoperative pain following surgical extraction of third molars in comparison to placebo or active comparators. At least one of the following outcomes was required to be reported in eligible studies: Pain intensity following surgery is assessed within 72 h using either a visual analogue scale (VAS) or numerical rating scale (NRS). The frequency of adverse events (AEs). Non-randomized studies, observational designs, reviews, case reports, conference abstracts, and studies that did not report pertinent outcomes were excluded. There were no limitations on the language or publication year. The study was carried out in compliance with predetermined eligibility criteria and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) principles to reduce potential bias, even though the protocol was not prospectively registered [12]. Information sources and search strategy From the inception of the search to January 2025, we conducted a systematic search of the following electronic databases: PubMed, Scopus, Web of Science, and Google Scholar. Additional queries were conducted in the WHO International Clinical Trials Registry Platform and ClinicalTrials.gov to identify unpublished or ongoing studies. The search strategy was established utilizing a blend of Medical Subject Headings (MeSH) and free-text terminology pertinent to pregabalin, third molar surgery, and postoperative discomfort. An instance of the PubMed search methodology is as follows: (“Pregabalin”[MeSH] OR pregabalin OR lyrica) AND (“Molar, Third”[MeSH] OR “third molar” OR “wisdom tooth”) AND (“Tooth Extraction”[MeSH] OR “oral surgery”) AND (“Postoperative Pain”[MeSH] OR “postoperative pain” OR analgesia OR “Visual Analog Scale” OR VAS) AND (“Randomized Controlled Trial”[Publication Type] OR randomized OR placebo). Equivalent search strategies were adapted for other databases. The complete search queries for each database are provided in Supplementary Table S1. Additionally, we conducted a screening of the reference lists of the included articles, google scholar, and pertinent systematic reviews to identify additional eligible studies. Selection and data collection process Abstracts and titles were independently evaluated by two evaluators in accordance with predetermined eligibility criteria. The same evaluators independently retrieved and evaluated the full texts of potentially relevant studies. The rationale for exclusion was recorded. A PRISMA 2020 flow diagram (Fig. 1) summarizes the study selection procedure. The PRISMA 2020 checklist is included as Supplementary Table S2. PRISMA flowchart Two evaluators independently extracted data using a standardized data extraction form. Discrepancies were resolved by consensus after the extracted data were cross-checked. The authors of the study were contacted for clarification when data that was essential was absent. The subsequent data items were extracted: Study characteristics include the author, year, country, design, sample size, and timing of medication administration. Intervention details: pregabalin dosage, schedule, and co-administered medications. Comparator: active treatment or placebo. The following are the outcomes: pain intensity (VAS/NRS) and adverse events. Follow-up timepoints: intervals for evaluating discomfort and adverse events (e.g., 2, 4, 6, 12, 24, 48, and 72 h). Risk of bias The Cochrane Risk of Bias 2 (RoB 2) instrument was employed to evaluate the risk of bias of the included studies. This instrument assesses five critical domains: The randomization process (D1), Deviations from intended interventions (D2), Missing outcome data (D3), Measurement of the outcome (D4), and Selection of the reported result (D5). Each domain was classified as Low risk, some concerns, or High risk. The overall assessment of each study was determined by the least favorable domain rating. Studies that were rated as High risk in any domain were assessed as High risk overall, while those with at least one some concern but no High risk were assessed as Some concerns overall. Studies that were rated as Low risk in all domains were assessed as Low risk overall [13]. Synthesis methods Our analysis focused on postoperative pain intensity (VAS) as the primary outcome, while adverse events were evaluated as secondary outcomes. Furthermore, the subgrouping of pain results by time of assessment (2, 4, 6, 8, 12 h, and 24 h postoperatively) and adverse event results by pregabalin dose (50, 75, and 300 mg) was implemented. Review Manager (RevMan 5.4.1, Cochrane Collaboration) was implemented to execute the meta-analysis. In addition to the number of participants in each group, we included the mean and standard deviation (SD) of pain scores for the pregabalin and control groups at each time point. The total number of participants randomized in each group and the number of participants with at least one adverse event were incorporated into the analysis of adverse events. The cumulative effect measure was estimated using a random-effects model and shown as the mean difference (MD) for VAS and the odds ratio (OR) for adverse events, with a standard error and 95% confidence interval (CI) for each statistic. Using the I² statistic, between-study heterogeneity was determined and classified as low (25%), moderate (50%), or high (75%). Certainty assessment The certainty of evidence for each outcome was evaluated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology. This methodology assesses evidence quality across five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. The evaluation was conducted with GRADEpro GDT [14], and a Summary of Findings table was created to explain the principal outcomes together with their respective certainty ratings. Result Study selection The database search yielded 154 records. After the removal of duplicates, 43 unique citations were screened. Of these, 14 articles were obtained for full-text review. The qualitative synthesis includes six RCTs that met the criteria for eligibility [10, 15–19]. Four of these studies [10, 16, 17, 19] provided adequate and consistent data to be included in the quantitative meta-analysis. The PRISMA 2020 flowchart (Fig. 1) illustrates the study selection process. Study characteristics The study included six RCTs published between 2001 and 2024, with sample sizes spanning from 24 to 198 participants (total n = 545). Four of the trials were parallel-group RCTs, while two utilized a split-mouth design. Trials were implemented in the United Kingdom, China, Spain, Iran, and Brazil. Pregabalin doses were administered either preoperatively (1 h prior to surgery) or postoperatively, with a range of 50 mg to 300 mg. Placebo, ibuprofen, or paracetamol were utilized as comparators. In certain investigations, pregabalin was administered in conjunction with conventional analgesics, such as paracetamol or dexamethasone. Postoperative pain intensity (VAS or NRS) was the primary outcomes. The secondary outcomes was adverse events. Table 1 contains a comprehensive recapitulation of the studies that were incorporated. Table 1Characteristics of Included Randomized Controlled TrialsAuthor (Year)CountryDesignN (total)Time of drug administrationIntervention (Pregabalin)ComparatorOutcomes (Pain VAS/NRS, Rescue, AEs)Time PointsKey FindingsHill et al. (2001)UKRCT, double-blind, parallel198 randomized; (Placebo and PGB300:n = 50, PGB75 and Ibuprofen: n = 49)after surgery (post-op)Pregabalin 50 mg or 300 mg PO, single dosePlacebo; Ibuprofen 400 mgpain relief (PR), PID, PRID, time to onset/duration of analgesia, global impression, adverse events (AEs)0.5–12 h (clinic), up to 24 h (home diary)Pregabalin 300 mg significantly better than placebo and ibuprofen (longer duration, higher global score). More adverse events in pregabalin 300 mg group.Hill et al. (2009)UKRCT (analgesic trial, ECG substudy)198post-opPregabalin 50 mg or 300 mg POIbuprofen 400 mg; placeboECG abnormalities, PR, AEs30 min post-analgesicECG changes minor, not significant. Pregabalin included as study drug; safety data noted.Cheung et al. (2012)ChinaRCT, double-blind, crossover34 completed (40 recruited)1 h pre-op or 1 h post-op (cross-over)Pregabalin 75 mg PO,Placebo (cross-over control)Pain scores (rest/mouth opening), AUC, rescue, AEs2–72 hPost-op pregabalin superior to pre-op for analgesic efficacy. No difference in rescue or AEs.Olmedo-Gaya et al. (2015)SpainRCT, double-blind60 (30 pregabalin, 30 control)1 h pre-op and 1 h post-opPregabalin 75 mg PO (+ paracetamol 650 mg every 8 h for 2 days)No pregabalin (+ paracetamol 650 mg every 8 h for 2 days)Pain VAS, VRS, rescue med, swelling, AEs, global impression1, 2, 4, 6, 8, 12, and 24 hNo significant VAS diff. Rescue use reduced with pregabalin. More AEs in pregabalin.Latifi et al. (2023)IranRCT, double-blind, split-mouth24 (48 surgeries)post-opPregabalin 75 mg PO single doseIbuprofen 400 mg POVAS (2–24 h), rescue ibuprofen use, AEsBaseline to 24 h (every 2 h)Pregabalin had lower VAS at 2 h, fewer rescue doses in 24 h. No detailed AE reporting.Diniz et al. (2024)BrazilRCT, triple-blind, split-mouth311 h pre-opPregabalin 150 mg (+ dexamethasone 8 mg)Placebo (+ dexamethasone 8 mg)VAS pain, STAI anxiety, rescue meds, sedation, AEs2,4,6,8,12,16,24, and 48 hPregabalin + dexamethasone significantly reduced pain (2–48 h), anxiety, and rescue use. increased sedation. No significant AEs. Characteristics of Included Randomized Controlled Trials Risk of bias The risk of bias assessment was conducted for the six studies that were included. The findings indicated that: In light of the presence of at least one domain with a high risk, three studies [15, 17, 18] were determined to have an overall high risk of bias. Two studies [10, 19] did not contain any High-risk domains; however, they did exhibit one or more domains with some concerns, resulting in an overall judgment of some concerns. One study [16] was rated as Low risk across all domains, indicating an overall low risk of bias (Fig. 2). Risk of bias summary including the overall risk of bias based on the included studies In conclusion, three of the six studies were classified as having a high risk of bias, two as having some concerns, and only one as having a low risk. The results of this review should be interpreted with the knowledge that the methodological quality of a significant number of the included studies is limited, as indicated by these findings (Fig. 3). Risk of bias graph including the overall risk of bias based on the investigated items Synthesis of results Pain intensity (VAS) Four studies [10, 16, 17, 19] were included in the meta‑analysis. Among them, one study evaluated only postoperative pain scores, another focused exclusively on adverse events, and the remaining two studies assessed both postoperative pain scores and adverse events. The pooled analysis indicated a decrease in postoperative pain intensity favoring pregabalin over control (MD = − 0.99, 95% CI − 1.46 to − 0.52; p < 0.0001) (Fig. 4). Significant heterogeneity was noted among the included comparisons (I² = 91%), reflecting considerable variability among studies and postoperative evaluation timepoints. Therefore, this finding must be regarded with caution, as variations in study design, intervention methods, and repeated measurements over time may have affected the aggregated estimate. Forest plot of postoperative pain intensity in pregabalin versus control groups The significant heterogeneity seen may be attributed to differences in comparator types and postoperative assessment timepoints among the included studies. Subgroup studies were conducted to examine these probable sources. Since all trials examined VAS using a consistent pregabalin dosage of 75 mg, dose–response effects could not be studied. The leave-one-out analysis revealed that excluding the study by Diniz et al. (2024) decreased heterogeneity from 91% to 0%, indicating that this study was a significant contributor to variability. In the primary analysis, pregabalin significantly reduced postoperative pain intensity. However, after excluding Diniz et al. (2024), the pooled estimate was markedly attenuated to MD = − 0.03 (95% CI: −0.21 to 0.15) and was no longer statistically significant (p = 0.75), indicating that the overall result was highly sensitive to the inclusion of this study (Supplementary Figures S1-3). The meta-analysis encompassed three studies that reported postoperative pain scores using a 0–10 VAS scale. All three investigations reported data at 2, 4, 6, 8, 12, and 24 h following the surgery. The MD for pain scores was − 1.11 (95% CI: −1.73, − 0.49, p = 0.0004, I²=92%), with pregabalin being the more favorable treatment (Fig. 5). The pooled MDs in pain scores were − 1.00 at 2 h, − 1.20 at 4 and 6 h, − 1.30 at 8 h, − 1.10 at 12 h, and − 0.81 at 24 h postoperatively. The aggregate effect was statistically significant; however, none of the individual timepoints achieved statistical significance as a result of the high heterogeneity and wide confidence intervals. Meta-analysis of VAS after third molar surgery by timepoint (2 h, 4 h, 6 h, 8 h, 12 h, 24 h) Leave-one-out sensitivity analysis showed that exclusion of Diniz et al. (2024) reduced heterogeneity from 92% to 0%; however, the pooled effect was no longer statistically significant (p = 0.60), indicating that this study was a major contributor to both the observed heterogeneity and the overall statistical significance of the timepoint-based analysis (Supplementary Figures S4–S6). Subgroup analysis conducted according to comparator type revealed significant disparities in treatment outcomes among studies. Pregabalin was associated with a substantial decrease in postoperative pain intensity in studies that employed placebo plus dexamethasone as the comparator (MD = − 2.04, 95% CI − 2.84 to − 1.24; I² = 94%). Conversely, no statistically significant differences were observed in studies that evaluated control comparators (MD = − 0.42, 95% CI − 0.96 to 0.13; I² = 0%) or ibuprofen (MD = 0.02, 95% CI − 0.17 to 0.20; I² = 0%). A significant subgroup difference was detected (p < 0.00001), indicating that the comparator type may be a significant source of heterogeneity in the aggregated analysis (Supplementary Figure S7). Adverse events The meta-analysis encompassed three studies that reported adverse events. One study reported pregabalin at a dosage of 50 mg, two studies reported 75 mg, and one study reported 300 mg. The aggregate OR for adverse events was 4.36 (95% CI: 2.52, 7.55, p < 0.00001, I²=77%), suggesting a substantial increase in risk with pregabalin in comparison to the control group. Subgroup aggregated ORs for 50 mg, 75 mg, and 300 mg doses were 1.18, 5.19, and 11.16, respectively (Fig. 6). The overall effect was substantial, and subgroup analysis revealed a statistically significant dose–response relationship, with a higher dose being associated with a higher risk of adverse events. Meta-analysis of adverse events after third molar surgery by pregabalin dose (50 mg, 75 mg, 300 mg) To assess the robustness of the adverse event findings, leave-one-out sensitivity analyses were conducted by sequentially excluding each included study. The analyses showed that heterogeneity remained substantial across all scenarios (I² range 69%-83%), as reflected by persistently high I² values. Importantly, the direction of the pooled effect remained unchanged, consistently indicating a higher risk of adverse events with pregabalin compared with the control group, and the statistical significance of the overall effect was preserved in all leave-one-out analyses. This suggests that the heterogeneity in adverse events was not driven solely by any single study (Supplementary Figures S8–S10). However, given the limited number of studies and the fact that the 50 mg and 300 mg estimates were each derived from a single study, the apparent dose–response relationship should be interpreted cautiously. Certainty of evidence The certainty of evidence for all outcomes was rated as low according to the GRADE approach (Table 2). For postoperative pain intensity, the certainty of evidence was downgraded to low due to concerns regarding inconsistency and imprecision. The certainty of evidence about adverse events was graded as low, mostly due to inconsistency and imprecision. In summary, while pregabalin may offer a slight reduction of postoperative pain, the certainty of the estimated effects is constrained, and the heightened risk of adverse events must be judiciously evaluated in clinical decision-making. Table 2GRADE Summary of Findings: Effect of Pregabalin on Postoperative Pain and Adverse Events Following Third Molar SurgeryCertainty assessment№ of patientsEffectCertaintyImportance№ of studiesStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerationsPGB (+)PGB (-)Relative(95% CI)Absolute(95% CI)Postoperative pain (VAS)3randomised trialsnot seriousseriousnot seriousseriousnone688688-MD 0.99 lower(1.46 lower to 0.52 lower)⨁⨁◯◯LowCRITICALAdverse events3randomised trialsnot seriousseriousnot seriousseriousnone65/160 (40.6%)22/161 (13.7%) OR 4.36 (2.52 to 7.55)272 more per 1,000(from 148 more to 408 more)⨁⨁◯◯LowCRITICALCIConfidence interval, MD Mean difference, OR Odds ratio GRADE Summary of Findings: Effect of Pregabalin on Postoperative Pain and Adverse Events Following Third Molar Surgery MD 0.99 lower (1.46 lower to 0.52 lower) ⨁⨁◯◯ Low OR 4.36 (2.52 to 7.55) 272 more per 1,000 (from 148 more to 408 more) ⨁⨁◯◯ Low CIConfidence interval, MD Mean difference, OR Odds ratio Discussion This systematic review and meta-analysis synthesized evidence from six RCTs involving 545 patients ascertaining the efficacy and safety of pregabalin for postoperative pain following third molar surgery. Three of these six studies reported postoperative pain scores on a 0–10 VAS. The pooled analysis indicated that pregabalin significantly lowered pain scores compared with control, with an overall mean difference of − 1.11 (p = 0.0004). However, this result was accompanied by substantial heterogeneity (I² = 92%), and none of the individual postoperative timepoints from 2 to 24 h reached statistical significance. Importantly, leave-one-out sensitivity analysis showed that exclusion of Diniz et al. (2024) reduced heterogeneity from 92% to 0%, but the pooled effect was no longer statistically significant (p = 0.60). This indicates that the overall pain finding was highly sensitive to the inclusion of this study and should therefore be interpreted with caution. Even though the pooled analysis demonstrated a statistically significant reduction in postoperative pain, the clinical relevance of this finding remains uncertain. The uncertainty surrounding the analgesic effect was further supported by the sensitivity analyses. In the primary pain analysis, pregabalin was associated with a statistically significant reduction in postoperative pain intensity (MD = − 0.99, 95% CI: −1.46 to − 0.52). However, after excluding Diniz et al. (2024), heterogeneity decreased from 91% to 0%, while the pooled estimate was markedly attenuated to MD = − 0.03 (95% CI: −0.21 to 0.15) and became statistically non-significant (p = 0.75). This finding suggests that the apparent analgesic benefit was largely influenced by Diniz et al. (2024), rather than being consistently reproduced across all included studies. A recent systematic review in dental pain research has suggested that the minimal clinically important difference (MCID) for VAS scores is approximately 1–2 points [20]. In this context, the observed effect size lies at the lower boundary of clinical significance and may therefore represent only a marginal or borderline clinically meaningful benefit. Importantly, MCID is not a fixed value and may vary depending on the clinical context, baseline pain intensity, patient expectations, as well as study design [21]. Thus, while pregabalin appears to yield a statistically detectable reduction in pain, its clinical significance from a patient-centered perspective may be limited. From a clinical perspective, the modest analgesic benefit should be weighed against the increased risk of adverse events. Although pregabalin reduced postoperative pain by approximately 1 point on the VAS scale, this effect was near the lower boundary of the MCID and became statistically non-significant in sensitivity analyses after exclusion of Diniz et al. (2024). In contrast, the increased risk of adverse events was more consistent, with a pooled OR of 4.36 and preservation of statistical significance across leave-one-out analyses. Therefore, the benefit–harm balance appears uncertain and may not favor routine use of pregabalin as a primary analgesic after third molar surgery, particularly when effective and well-established alternatives such as NSAIDs and corticosteroids are available. Following third molar surgery, the release of inflammatory mediators peaks within the first two to three postoperative days. This cascade induces vasodilation and promotes vascular permeability, thereby facilitating fluid accumulation and leukocyte infiltration at the surgical site. These pathophysiological processes are closely tied to the development of postoperative pain, edema, and functional limitation in procedures involving impacted teeth [22–24]. Clinically, pain of acute character typically reaches its maximum intensity between 3 and 6 h after surgery and may persist for 48 to 72 h before gradually declining [17, 25]. More specifically, inflammation arising from surgical trauma at the operative site and adjacent tissues is closely linked to the extent of tissue injury and represents an essential component of the healing process [26, 27]. Thus, the use of careful and minimally traumatic surgical techniques is critical to dampening excessive inflammatory responses. The classic clinical manifestations of inflammation include pain, swelling, erythema, and impaired function, which are mediated by a complex interplay of biochemical pathways. Key mediators include prostaglandins, histamine, bradykinin, and serotonin [28]. Pregabalin, chemically designated as (S)-3-(aminomethyl)-5-methylhexanoic acid, is the active S-enantiomer of a racemic 3-isobutyl γ-aminobutyric acid analogue [29]. Several studies have documented the significant neuroprotective properties of pregabalin across various experimental models. Since neuronal injury plays a central role in the development of neuropathic pain, the protective effects of pregabalin on neural tissues are thought to contribute to its capacity to alleviate neuropathic pain symptoms [30]. The pharmacological activity of pregabalin is primarily mediated through various signaling pathways. The pharmacokinetics of pregabalin are dose-dependent, exhibiting rapid absorption, linear disposition, and predictable plasma concentrations. Following oral administration, pregabalin is efficiently absorbed, widely distributed across tissues, while also being capable of crossing the blood–brain barrier (BBB). Peak plasma levels are typically achieved within approximately one hour, supporting this time point as optimal for ascertaining maximal pharmacological effects. The compound does not undergo hepatic metabolism, exhibits negligible plasma protein binding, and is predominantly eliminated in an unchanged form via renal excretion, with more than 90% recovered in urine. Its elimination half-life averages 6.3 h, while complete clearance generally takes place within 24–48 h. Importantly, pregabalin presents minimal potential for drug–drug interactions and does not induce dependence [15, 29, 31]. Available studies appraising the efficacy of pregabalin in acute postoperative pain have yielded inconsistent results, which may be assigned to variations in dosage, treatment regimen, and surgical procedures. The third molar surgery model is a well-established and validated framework for evaluating analgesic efficacy, typically using NSAIDs as reference treatments [17, 32]. Nevertheless, investigations specifically ascertaining pregabalin within this model remain limited. Latifi et al. reported that a single oral dose of pregabalin (75 mg) generated a pronounced analgesic effect within 2 h following impacted mandibular third molar extraction compared to cases treated with ibuprofen. Most patients needed complementary analgesics at 4 h post-surgery. Further, patients receiving pregabalin required significantly fewer supplemental analgesics along the first 24 h postoperatively compared with those treated with ibuprofen [19]. In another study, Hill et al. reported that a single 300-mg dose of pregabalin exhibited superior efficacy compared with both placebo and the 50-mg dose across all assessed parameters. The 50-mg dose did not show a significant difference from placebo at any evaluation point. Ibuprofen, included as an active comparator, was superior to placebo, thereby confirming adequate assay sensitivity of the study. While the onset of analgesia appeared to slightly favor ibuprofen, the difference was not statistically significant. In contrast, the duration of analgesic effect was significantly longer with pregabalin 300 mg, with superiority noted between 7 and 10 h for pain relief (PR), pain intensity difference (PID), and pain relief intensity difference (PRID) [17]. Meanwhile, Olmedo-Gaya found no significant differences in pain intensity, as measured by VAS, between the pregabalin and control groups. Nevertheless, patients who received pregabalin required fewer rescue medication tablets compared with controls. Thus, they reported that pregabalin administration was linked to more stable pain control, characterized by fewer peaks in pain intensity following third molar surgery [10]. In Cheung et al. research, it was reported that postoperative administration of oral pregabalin 75 mg exhibited better analgesic efficacy than preoperative administration following third molar surgery under local anesthesia. Indeed, they documented no superior analgesic efficacy with low-dose preoperative pregabalin over postoperative pregabalin in third molar surgery under local anesthesia, revealing no pre-emptive analgesic effect [15]. Nevertheless, Diniz et al. reported that administration of pregabalin 150 mg in combination with dexamethasone (8 mg) one hour prior to surgery provided superior analgesic efficacy across most postoperative time points as compared with dexamethasone alone [16]. The discrepancy among these findings may be attributed to several factors such as differences in dose, timing, and multimodal strategies. The adjunctive use of corticosteroids may have contributed to the broader anti-inflammatory and analgesic profile, while the higher pregabalin dose may have been sufficient to generate clinically meaningful benefits. The rationale for combining analgesic agents is based on three primary objectives: (i) to minimize acute pain both intraoperatively and during the postoperative period; (ii) to inhibit maladaptive central nervous system (CNS) modulation of nociceptive signals, thereby lowering the risk of pain memory formation; and (iii) to reduce the likelihood of pain chronification following surgery. However, in patients with pre-existing pain, central sensitization of nociceptors may already be established, which can compromise the effectiveness of pre-emptive analgesic strategies. The subgroup analysis by comparator type provided further insight into the observed heterogeneity. Pregabalin was associated with a significant reduction in postoperative pain only in studies using placebo plus dexamethasone as the comparator, whereas no significant benefit was observed in comparisons with control or ibuprofen. The statistically significant subgroup difference suggests that comparator type may have substantially influenced the pooled estimate. This is clinically plausible because active comparators, such as ibuprofen or corticosteroid-containing regimens, may reduce the apparent incremental benefit of pregabalin. However, the persistence of high heterogeneity within the placebo plus dexamethasone subgroup indicates that comparator type alone does not fully explain the inconsistency, and other factors, including timing of pain assessment, surgical variability, analgesic rescue protocols, and repeated postoperative measurements, may also have contributed. Three studies contributed data to the adverse event analysis. Pregabalin was associated with a significantly higher risk of adverse events compared with control, with a pooled odds ratio of 4.36 (95% CI: 2.52 to 7.55; p < 0.00001). Although substantial heterogeneity was present (I² = 77%), the leave-one-out sensitivity analyses showed that the increased risk remained statistically significant after sequential exclusion of each study, and the direction of effect consistently favored a higher adverse event rate with pregabalin. Heterogeneity also remained substantial across these analyses (I² range: 69%–83%), suggesting that variability in adverse event estimates was not driven by any single study. Therefore, unlike the pain outcome, the safety signal appeared relatively robust despite persistent heterogeneity. The broader literature on pregabalin safety is consistent with the significantly heightened incidence of adverse events observed in the present analysis. The dose-dependent pattern of pregabalin-related adverse events, including dizziness, somnolence, cognitive impairment, blurred vision, and balance disturbances, has been consistently reported in previous systematic reviews and pharmacovigilance data [33, 34]. In a comprehensive systematic review and meta-analysis of randomized controlled trials, Zaccara et al. [34] found that as the dose of pregabalin increased, so did the incidence of numerous neurological and coordination-related adverse events. This suggests a selective dose–response relationship. Likewise, prescribing information and pooled safety analyses suggest that dizziness and somnolence take place at a significantly higher frequency at daily doses of 300–600 mg than at lower doses, such as 75–150 mg [35]. The incidence of adverse events was significantly higher than that of controls even though several included comparisons used relatively low pregabalin doses, including 50 mg and 75 mg. However, the highest adverse event estimate was observed in the 300 mg subgroup, supporting a possible dose-related tolerability concern. This suggests that even low perioperative doses may impact tolerability in susceptible individuals. This finding is particularly relevant in the context of third molar surgery, where patients are often young and otherwise healthy, and the expected postoperative pain is usually transient and manageable with established analgesics. In such a setting, even mild-to-moderate adverse events such as dizziness, somnolence, nausea, or impaired coordination may be clinically important, as they can affect daily activities, driving, work or study performance, and patient satisfaction. Given that the observed analgesic benefit was modest and uncertain in sensitivity analyses, the increased adverse event risk may outweigh the limited pain reduction in many routine clinical scenarios [36]. Whereas the multimodal approach and preemptive strategies highlight the potential benefits of pregabalin in postoperative pain management, these should be carefully weighed against its adverse effect profile, as safety considerations remain equally critical in determining its clinical utility. Even though the use of pregabalin has been shown to diminish the need for both opioid and non-opioid analgesics, thereby potentially lowering the incidence of their associated adverse effects, pregabalin itself has also been linked to certain adverse events [37]. Adverse effects of pregabalin are more frequently observed with prolonged administration and higher dosages. They commonly include dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, myoclonus, and, in rare cases, gynecomastia [38]. In Diniz et al. investigation, five patients reported adverse effects such as drowsiness, dizziness, and nausea [16]. Likewise, Ahiskalioglu et al. ascertained patients undergoing orthognathic surgery and reported a higher incidence of nausea and vomiting in the placebo group as compared with those treated with pregabalin 150 mg, though this difference did not reach statistical significance [39]. In third molar surgery, Hill et al. observed that adverse effects such as dizziness, drowsiness, and vomiting were more frequent in patients receiving pregabalin 300 mg [17]. Olmedo-Gaya et al. also identified drowsiness and nausea as the most prominent adverse effects at a 75 mg dose, exhibiting a significant rise compared with controls [10]. In contrast, Degirmenci and Yalcin found no significant differences between groups, though adverse effects occurred more often with pregabalin at 75 mg and 150 mg [8]. Further, Cheung et al. reported postoperative dizziness in 5.9% of patients treated with pregabalin 75 mg, though this incidence was not statistically different from that of the control group [15]. In addition to the commonly reported adverse effects such as dizziness, drowsiness, and nausea, the potential cardiovascular effects of pregabalin should also be taken into account. A study investigating healthy adults undergoing third molar extraction reported ECG abnormalities both pre- and post-operatively in patients receiving analgesics, including pregabalin. Preoperatively, 44 patients exhibited minor ECG changes, such as rsR complex patterns, nonspecific ST elevations, abnormal P-wave axes, and single atrial premature beats. Postoperatively, 60 patients presented similar minor changes, with a few clinically relevant abnormalities, including marked ST elevation, marked ST depression, and one case of right bundle branch block (RBBB), necessitating cardiology referral. Among them, one single ECG abnormality was observed in a patient who received 300 mg of pregabalin postoperatively, presenting as an acute injury pattern with marked ST elevation (> 5–8 mm in V2 and 2–3 mm in V1). The abnormality resolved completely within two hours. The precise etiology of this event remains uncertain. Although these findings were not statistically significant, they emphasize the need for caution and monitoring in patients receiving pregabalin, particularly in those with underlying cardiac conditions [18]. The analgesic efficacy of pregabalin is limited in comparison to alternative medications employed in third molar surgery. The incorporation of dexmedetomidine into local anesthetics has been associated with a significantly greater reduction in postoperative pain, with aggregated estimates revealing a reduction of roughly − 2.32 points on the VAS at 6–12 h postoperatively [20]. Corticosteroids such as dexamethasone and methylprednisolone primarily function through anti-inflammatory mechanisms rather than providing immediate analgesia. Network meta-analyses suggest that dexamethasone is extremely beneficial in mitigating postoperative inflammatory sequelae, such as edema and trismus, and might also alleviate early postoperative pain, although its analgesic superiority compared to other corticosteroids is less consistent [40]. Likewise, methylprednisolone has been demonstrated to ameliorate postoperative outcomes, especially trismus and edema, though it does not provide a substantial benefit in pain relief relative to other medications [41]. In contrast to these medicines, pregabalin influences neuropathic pain pathways through regulating calcium channel function, potentially explaining its moderate yet persistent influence on postoperative pain. However, in contrast to corticosteroids, it does not mitigate the inflammatory aspect of postoperative pain, and unlike dexmedetomidine, its analgesic efficacy appears somewhat diminished. The clinical applicability of pregabalin in third molar surgery should therefore be considered limited. Third molar extraction is commonly performed in young, ambulatory patients, for whom postoperative pain is generally short-lived and can often be managed effectively with NSAIDs, acetaminophen, corticosteroids, or local anesthetic adjuncts. In this context, the addition of pregabalin may offer only a small incremental analgesic benefit while increasing the likelihood of adverse events such as dizziness and drowsiness. These adverse effects may be particularly relevant in outpatient dental surgery, where rapid recovery, safe ambulation, and return to normal activities are important. Accordingly, pregabalin should not be considered a routine first-line analgesic for all patients undergoing third molar surgery. Its use may be more appropriate in selected patients at higher risk of severe postoperative pain, patients in whom conventional analgesics are contraindicated or insufficient, or as part of a carefully planned multimodal analgesic strategy. The heterogeneity identified in the pain analyses appeared to be strongly influenced by the study conducted by Diniz et al. (2024). This was confirmed by leave-one-out sensitivity analyses, in which exclusion of this study reduced heterogeneity from 91% to 0% and rendered the pooled pain effects statistically non-significant. Therefore, Diniz et al. (2024) contributed not only to between-study heterogeneity but also to the statistical significance of the pooled analgesic estimate. One possible explanation is the specific design of this trial, in which pregabalin was evaluated in combination with dexamethasone. Because dexamethasone has established anti-inflammatory and analgesic properties, its use as a co-intervention may have modified the observed treatment effect and limited the comparability of this study with trials evaluating pregabalin against other comparators, such as ibuprofen or standard control. These findings highlight the importance of accounting for co-interventions and comparator type when interpreting the pooled analgesic effect. A major limitation of this analysis was the inclusion of studies with heterogeneous comparator groups, encompassing both placebo and active therapies, such as NSAIDs and corticosteroids. The comparators revealed significant differences in analgesic efficacy and methods of action, potentially impacting the observed effect’s magnitude and contributing to the considerable heterogeneity. Specifically, active comparators with recognized analgesic or anti-inflammatory properties may have diminished the perceived efficacy of pregabalin by lessening the disparities between groups. This concern is especially important in trials when co-interventions, such as corticosteroids, were utilized, potentially obscuring the real analgesic impact of pregabalin. Another important limitation is the instability of the pooled pain estimate. Sensitivity analyses showed that removal of a single study, Diniz et al. (2024), eliminated statistical significance and reduced heterogeneity to 0%, indicating that the analgesic efficacy finding was not robust across all included studies. In contrast, the adverse event finding remained statistically significant in leave-one-out analyses, although heterogeneity persisted. In addition, the dose-specific adverse event estimates were based on very few studies, with the 50 mg and 300 mg subgroups each represented by a single study comparison. Therefore, conclusions regarding dose–response safety patterns should be regarded as exploratory. Hence, the aggregated estimations need to be regarded with caution. Future randomized trials employing standardized comparator groups, especially placebo-controlled designs, are essential to accurately isolate as well as quantify the actual benefit of pregabalin in this therapeutic context. Conclusion This meta-analysis suggests that pregabalin may provide a modest reduction in postoperative pain after third molar surgery; however, the clinical relevance and robustness of this benefit remain uncertain. The observed reduction was approximately 1 point on the VAS scale, near the lower boundary of the MCID, and the analgesic effect became statistically non-significant after exclusion of Diniz et al. (2024). Therefore, the analgesic effect should be interpreted cautiously. In contrast, pregabalin was consistently associated with a higher incidence of adverse events, and this safety signal remained significant in sensitivity analyses. A possible dose-related increase in adverse events was observed, but this finding should be considered exploratory due to the limited number of studies within each dose subgroup. Therefore, the benefit–harm balance does not clearly support routine use of pregabalin as a first-line analgesic after third molar surgery. Overall, the certainty of evidence is limited by substantial heterogeneity, heterogeneous comparator groups, co-interventions, and the sensitivity of the pain outcome to a single study. Additional well-designed, placebo-controlled randomized trials using standardized doses, comparator groups, rescue analgesic protocols, and postoperative assessment timepoints are required to clarify the true magnitude and clinical relevance of pregabalin’s analgesic effect in this setting. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Acknowledgements Not applicable. Abbreviations Non-steroidal anti-inflammatory drug Randomized controlled trial Visual analogue scale Numerical rating scale Adverse event Preferred Reporting Items for Systematic Reviews and Meta-Analyses Risk of Bias 2 Standard deviation Mean difference Odds ratio Confidence interval Blood–brain barrier Pain relief Pain intensity difference Pain relief intensity difference Central nervous system Minimal clinically important difference Authors’ contributions JL conceived and designed the study, supervised the methodology, conducted the database search, performed the data extraction and statistical analysis, and drafted the manuscript. AW contributed to study selection, verified the extracted data, assisted with risk-of-bias assessment, and critically reviewed and revised the manuscript for important intellectual content. Both authors read and approved the final manuscript. Funding Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Data Availability Statement No datasets were generated or analysed during the current study.